The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow.
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar ...
Johnson & Johnson has won Food and Drug Administration ... makes Spravato the first and only monotherapy for adults with major depressive disorder who have had an inadequate response to at least ...
Johnson & Johnson (NYSE ... schizophrenia and depression related to bipolar I or II disorder. It may also soon obtain approval for major depressive disorder. The blockbuster drug could generate ...
The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow.